Bioprox Healthcare invests €30 million in upgrading its production facilities

Bioprox Healthcare is pleased to announce a significant expansion of its manufacturing capabilities, further establishing its status as a leader in the probiotics sector. As leading French Contract Development and Manufacturing Organisation (CDMO), Bioprox boosts production capacity with this strategic investment.

In order to meet the ever-growing market demands within probiotics’ sector, Bioprox has undertaken a recent modernisation and an extensive enhancement of its facilities. From fermentation to downstream processing, including liquid and freeze-drying outputs, Bioprox Healthcare will keep providing a full spectrum of services, ranging from lab scale to pilot and industrial scale.

This major investment marks a crucial step in our mission to improve efficiency and delivery, ensuring we meet the needs of our current and future clients.

Key figures of the expansion:

• 100% increase in fermentation capacity
• 65% increase in overall productivity
• New state-of-the-art technology for bioreactors

Discover how Bioprox Healthcare can support your projects and drive your success.